Ardelyx Reports Strong IBSRELA Growth, Positive 2026 Revenue Guidance, and Pipeline Progress
ARDX sits 99% above its 52-week low of $3.21.
Summary
Ardelyx reported strong Q4 and full-year 2025 financial results, driven by significant IBSRELA revenue growth and providing optimistic 2026 guidance, alongside key pipeline advancements.
Key Events · Earnings and Guidance · ARDX
-
IBSRELA Revenue Surges
IBSRELA revenue grew 73% year-over-year to $274.2 million for full-year 2025, with Q4 2025 revenue reaching $86.6 million, a 61% increase from Q4 2024.
-
Strong 2026 IBSRELA Guidance
The company expects full-year 2026 IBSRELA revenue to be between $410 million and $430 million, representing at least 50% growth, and projects $1 billion in annual revenue by 2029.
-
XPHOZAH Revenue Update
XPHOZAH revenue for 2025 was $103.6 million, a decrease from $160.9 million in 2024, with 2026 guidance set between $110 million and $120 million.
-
Pipeline Expansion
Ardelyx launched a Phase 3 trial (ACCEL) for IBSRELA in Chronic Idiopathic Constipation (CIC) in Q1 2026, with topline results expected in 2H 2027. It also advanced RDX10531, a next-generation NHE3 inhibitor, towards an IND submission in 2H 2026.
Analysis · ARDX · Life Sciences
Ardelyx's full-year 2025 results highlight robust growth for IBSRELA, which saw a 73% increase in revenue and is projected for at least 50% growth in 2026, targeting $1 billion by 2029. This strong performance is a significant positive for the company's commercial trajectory. While XPHOZAH revenue declined in 2025, its 2026 guidance indicates a return to modest growth. The launch of a Phase 3 trial for IBSRELA in Chronic Idiopathic Constipation (CIC) and the advancement of a next-generation NHE3 inhibitor (RDX10531) demonstrate a commitment to pipeline expansion and long-term value creation. Despite an increased net loss for 2025, the company's healthy cash position and positive cash flow generation in the second half of 2025 provide a solid financial foundation for its strategic initiatives. Investors should monitor the continued commercial execution of IBSRELA and the progress of the new clinical programs.
At the time of this filing, ARDX was trading at $6.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $3.21 to $8.40. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.